NO20065487L - Modulering av immunglobulinproduksjon og atopiske forstyrrelser - Google Patents

Modulering av immunglobulinproduksjon og atopiske forstyrrelser

Info

Publication number
NO20065487L
NO20065487L NO20065487A NO20065487A NO20065487L NO 20065487 L NO20065487 L NO 20065487L NO 20065487 A NO20065487 A NO 20065487A NO 20065487 A NO20065487 A NO 20065487A NO 20065487 L NO20065487 L NO 20065487L
Authority
NO
Norway
Prior art keywords
modulation
immunoglobulin production
atopic disorders
disorders
atopic
Prior art date
Application number
NO20065487A
Other languages
English (en)
Norwegian (no)
Inventor
Mary Collins
Marion Kasaian
Nancy L Wood
Debra D Donaldson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20065487L publication Critical patent/NO20065487L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20065487A 2004-05-19 2006-11-28 Modulering av immunglobulinproduksjon og atopiske forstyrrelser NO20065487L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57240704P 2004-05-19 2004-05-19
PCT/US2005/017514 WO2005112983A2 (en) 2004-05-19 2005-05-19 Modulation of immunoglobulin production and atopic disorders

Publications (1)

Publication Number Publication Date
NO20065487L true NO20065487L (no) 2006-12-18

Family

ID=35428852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065487A NO20065487L (no) 2004-05-19 2006-11-28 Modulering av immunglobulinproduksjon og atopiske forstyrrelser

Country Status (15)

Country Link
US (1) US20060024268A1 (enExample)
EP (1) EP1753458A4 (enExample)
JP (1) JP2008501042A (enExample)
KR (1) KR20070014181A (enExample)
CN (1) CN1980698A (enExample)
AU (1) AU2005244942A1 (enExample)
BR (1) BRPI0510996A (enExample)
CA (1) CA2566333A1 (enExample)
EC (1) ECSP067014A (enExample)
IL (1) IL179243A0 (enExample)
MX (1) MXPA06013483A (enExample)
NO (1) NO20065487L (enExample)
RU (1) RU2006138704A (enExample)
WO (1) WO2005112983A2 (enExample)
ZA (1) ZA200609600B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
ZA200500480B (en) * 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
WO2004083249A2 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
WO2005030196A2 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
RU2007102287A (ru) * 2004-08-05 2008-09-10 Вайет (Us) Антагонисты активности рецептора интерлейкина-21
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2006111524A2 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
EP1890723A2 (en) * 2005-06-06 2008-02-27 Novo Nordisk A/S Stabilised il-21 compositions
US7914574B2 (en) * 2005-08-02 2011-03-29 Reva Medical, Inc. Axially nested slide and lock expandable device
US7592427B2 (en) * 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
PL1963369T3 (pl) 2005-11-28 2013-10-31 Zymogenetics Inc Antagoniści IL-21
CN101553501A (zh) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 Il-21变种
CA2671665A1 (en) * 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
EP2426146B1 (en) 2007-12-07 2016-02-17 ZymoGenetics, Inc. Anti-human IL-21 monoclonal antibodies
MX2010012812A (es) * 2008-05-23 2011-01-21 Wyeth Llc Metodos de tratamiento que utilizan proteinas de union del receptor de la interleucina-21.
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
CA2739357A1 (en) 2008-09-23 2010-04-08 Wyeth Llc Methods for predicting production of activating signals by cross-linked binding proteins
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
RS60050B1 (sr) 2011-01-18 2020-04-30 Bioniz Llc Kompozicije za modulaciju aktivnosti gama-c-citokina
WO2014205501A1 (en) 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
US11709169B2 (en) * 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2087911T3 (es) * 1989-04-28 1996-08-01 Riker Laboratories Inc Dispositivo de inhalacion de polvo seco.
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SE9502800D0 (sv) * 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
CA2312142A1 (en) * 2000-06-22 2001-12-22 An-Go-Gen Inc. Injection system for gene delivery
DK1451322T3 (da) * 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7556944B2 (en) * 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
CN1685063B (zh) * 2002-08-12 2011-12-21 新英格兰生物实验室公司 与基因沉默相关的方法和组合物
CA2501807A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Also Published As

Publication number Publication date
CA2566333A1 (en) 2005-12-01
ZA200609600B (en) 2010-04-28
WO2005112983A2 (en) 2005-12-01
WO2005112983A3 (en) 2006-10-05
MXPA06013483A (es) 2007-01-23
ECSP067014A (es) 2006-12-29
JP2008501042A (ja) 2008-01-17
KR20070014181A (ko) 2007-01-31
US20060024268A1 (en) 2006-02-02
RU2006138704A (ru) 2008-06-27
IL179243A0 (en) 2007-03-08
BRPI0510996A (pt) 2007-12-04
AU2005244942A1 (en) 2005-12-01
CN1980698A (zh) 2007-06-13
EP1753458A2 (en) 2007-02-21
EP1753458A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
NO20065487L (no) Modulering av immunglobulinproduksjon og atopiske forstyrrelser
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
NO20070189L (no) Immunoglobuliner
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY205342A (en) Bispecific 2+1 contorsbodies
WO2007141533A3 (en) Fkbp-l and uses thereof
TW200736274A (en) Immunoglobulins
UA102994C2 (ru) АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
WO2008123999A3 (en) Anti-ige antibodies
NO20082942L (no) Ligander som binder IL-4 og/eller IL-13
NZ599875A (en) Human il-23 antigen binding proteins
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX374291B (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
NO20084878L (no) Humanisert C-kit antistoff
MX2010008060A (es) Anticuerpos humanizados especificos para el factor von willerbrand.
WO2008143666A3 (en) Crystal structures of neuropilin fragments and neuropilin-antibody complexes
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
WO2021146320A8 (en) Antibody molecules to c5ar1 and uses thereof
SA518400027B1 (ar) TNF- a أجسام مضادة لـ وشظايا وظيفية منها

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application